NIOX Group plc

NIOX Group plc is a British public limited company specializing in medical devices for the diagnosis and management of respiratory diseases, particularly asthma. It develops and manufactures point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement devices, including the NIOX VERO and FeNO by NIOX range, which help healthcare professionals assess airway inflammation through simple, user-friendly tests aided by visual and audio cues. Founded in 2006 as Circassia Group and rebranded in 2022, the company is headquartered at The Oxford Science Park in Oxford, United Kingdom, with direct operations in the UK, US, Germany, Sweden, and China, plus a global distribution network spanning over 50 countries. NIOX Group plc reported £41.8 million in revenue for 2024, primarily from its NIOX products, with sales distributed across Asia Pacific, the United States, the EU, and the UK. Led by Executive Chairman Ian Johnson and CEO Jonathan Emms, it emphasizes corporate responsibility, ethical compliance, diversity, and environmental sustainability in its operations within the highly regulated medical diagnostics sector.